Mesoblast (ASX: MSB) — Company Overview, News & Financial Data
Mesoblast focuses on cell therapy products for various diseases, aiming to lead in developing innovative therapeutic solutions.
Mesoblast
Mesoblast is a biotechnology company that develops allogeneic cellular medicines based on its proprietary mesenchymal lineage cell therapy platform. The company focuses on developing cell-based treatments for severe inflammatory and cardiovascular conditions, including pediatric steroid-refractory acute graft-versus-host disease, chronic heart failure, end-stage ischemic heart failure, and chronic low back pain due to degenerative disc disease. Its platform utilizes culture-expanded mesenchymal lineage precursor and stem cells that modulate immune responses, suppress inflammation, and promote tissue repair. The company conducts clinical trials globally and maintains operational facilities across Australia, the United States, and Singapore.
Snapshot
Operations
Products and/or services of Mesoblast
- Pediatric Allogeneic Cell Therapy: Allogeneic mesenchymal stromal cell treatment designed for pediatric patients suffering from steroid-refractory acute graft-versus-host disease following bone marrow or hematopoietic stem cell transplantation. The therapy reduces systemic inflammation and promotes immune tolerance in pediatric populations.
- Adult Inflammatory Disease Cell Therapy: Intravenous mesenchymal lineage stem cell therapy evaluated in clinical studies for systemic inflammatory conditions, including severe acute respiratory distress syndrome caused by viral infections and biological treatment-resistant moderate-to-severe Crohn's disease.
- Advanced Heart Failure Therapy: Direct myocardial injection of allogeneic mesenchymal precursor cells targeting patients with chronic heart failure reduced ejection fraction and left ventricular assist device recipients, aiming to reduce recurrent cardiovascular hospitalizations and major adverse cardiac events.
- Degenerative Disc Disease Treatment: Direct intradiscal injection of allogeneic mesenchymal precursor cells combined with hyaluronic acid for patients with chronic low back pain caused by degenerative disc disease, focusing on long-term pain reduction and functional improvement.
- Allogeneic Cellular Manufacturing: Scalable industrial bioprocessing and cell culture manufacturing capabilities producing standardized, off-the-shelf mesenchymal lineage cell therapy products in bioreactor facilities under current Good Manufacturing Practice standards for global clinical supply.
- Cell Therapy Commercialization Partnerships: Strategic licensing, distribution, and commercial co-development agreements with global pharmaceutical companies to commercialize specialized cellular medicines across commercial markets in North America, Europe, and Asia-Pacific regions.
Mesoblast executive team
- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
- Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director
- Mr. James Michael O'BrienChief Financial Officer
- Mr. Peter T. Howard B.Sc., L.L.B.General Counsel & Corporate Executive
- Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer
- Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
- Mr. Justin Horst B.S.Head of Manufacturing
- Dr. Fiona See Ph.D.Senior VP & Head of Translational Research
- Mr. Marcelo SantoroChief Commercial Officer
- Ms. Niva Sivakumar B.Com., L.L.B.Joint Company Secretary